Fresenius Medical Care Reports Q1 2024 Results
Ticker: FMCQF · Form: 6-K · Filed: May 7, 2024 · CIK: 1333141
| Field | Detail |
|---|---|
| Company | Fresenius Medical Care Ag (FMCQF) |
| Form Type | 6-K |
| Filed Date | May 7, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: earnings, financial-results, non-gaap
Related Tickers: FMS
TL;DR
Fresenius Medical Care dropped Q1 2024 earnings report, watch out for non-GAAP numbers.
AI Summary
Fresenius Medical Care AG announced its first quarter results for the period ending March 31, 2024, on May 7, 2024. The company issued a press release detailing these results, which included non-GAAP financial measures.
Why It Matters
This filing provides investors with the company's latest financial performance, including key metrics and potentially non-GAAP figures that require careful interpretation.
Risk Assessment
Risk Level: low — This is a routine earnings release filing, not indicating any immediate operational or financial distress.
Key Players & Entities
- Fresenius Medical Care AG (company) — Registrant
- March 31, 2024 (date) — End of reporting period
- May 7, 2024 (date) — Date of press release
FAQ
What period do the reported first quarter results cover?
The first quarter results reported cover the period ending March 31, 2024.
When did Fresenius Medical Care announce its first quarter results?
Fresenius Medical Care announced its first quarter results on May 7, 2024.
What form is being filed with the SEC?
A Form 6-K report is being filed with the SEC.
Are the financial figures presented in the press release exclusively GAAP?
No, the attached Press Release contains non-GAAP financial measures.
What is the company's principal executive office address?
The company's principal executive offices are located at Else-Kröner Strasse 1, 61346 Bad Homburg, Germany.
Filing Stats: 563 words · 2 min read · ~2 pages · Grade level 15.6 · Accepted 2024-05-07 06:01:23
Filing Documents
- tm249581d2_6k.htm (6-K) — 13KB
- tm249581d2_ex99-1.htm (EX-99.1) — 63KB
- tm249581d2_ex99-2.htm (EX-99.2) — 400KB
- tm249581d2_ex99-1img001.jpg (GRAPHIC) — 18KB
- tm249581d2_ex99-1img003.jpg (GRAPHIC) — 277KB
- tm249581d2_ex99-1img004.jpg (GRAPHIC) — 155KB
- tm249581d2_ex99-2img001.jpg (GRAPHIC) — 10KB
- 0001104659-24-057631.txt ( ) — 1110KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DATE: May 7, 2024 Fresenius Medical Care AG By: /s/ Helen Giza Name: Helen Giza Title: Chief Executive Officer and Chair of the Management Board By: /s/ Martin Fischer Name: Martin Fischer Title: Chief Financial Officer and member of the Management Board